retatrutide glp-1 gip glucagon triple agonist 40mg Triple Agonism Based Therapies for

critical revision of the manuscript for important intellectual content

The effects of pharmaceutical and non-pharmaceutical treatments on bone outcomes such as BTMs and/or BMD are warranted

[DOI] [PubMed] [Google Scholar] 12.Green B.D., Gault V.A., Flatt P.R., Harriott P., Greer B., OHarte F.P.M

Providers should monitor weight, fasting glucose or insulin levels, hemoglobin A1c, and menstrual patterns

The 30-day minimum is a general guideline, not a hard cutoff

Zhang, J., Cai, W., Liu, D., Zheng, N., Wang, Y., Qiu, F., Zheng, H., Gan, H., Huang, Y., Zhou, Y., Yu, M., Xiong, S., Luo, G., Guo, J., Zhu, L., Zhang, Y., Ke, H., Liu, Y., Huang, G., Yu, C., Xu, J